Onderneming Urovant Sciences Ltd.
Aandelen
UROV
BMG9381B1081
Biotechnologie & Medisch Onderzoek
Vakgebied
Aantal werknemers: 70
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
James Robinson
CEO | Chief Executive Officer | 54 | 01-03-19 |
Ajay Bansal
DFI | Director of Finance/CFO | 62 | 28-10-19 |
Chief Tech/Sci/R&D Officer | 66 | - | |
Ryan Kubota
IRC | Investor Relations Contact | - | - |
Kenton Stewart
SAM | Sales & Marketing | - | 02-06-20 |
Nori Ebersole
HRO | Human Resources Officer | 60 | 01-12-17 |
Walt Johnston
PRN | Corporate Officer/Principal | - | 02-06-20 |
Christine Ocampo
AUD | Comptroller/Controller/Auditor | 51 | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James Hindman
BRD | Director/Board Member | 63 | 20-05-20 |
Sef P. Kurstjens
BRD | Director/Board Member | 60 | 01-07-18 |
James Robinson
CEO | Chief Executive Officer | 54 | 01-03-19 |
Director/Board Member | 59 | 27-12-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 32 743 396 | 5 633 501 ( 17,20 %) | 0 | 17,20 % |
Bedrijfsgegevens
Urovant Sciences Ltd.
11-12 Saint James's Square Suite 1
SW1Y 4LB, London
+
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,51% | 104 mld. | |
+3,22% | 97,42 mld. | |
+0,55% | 22,2 mld. | |
-16,53% | 21,23 mld. | |
-10,26% | 18,33 mld. | |
-42,33% | 16,35 mld. | |
-20,09% | 15,06 mld. | |
+5,47% | 13,98 mld. | |
+28,85% | 11,66 mld. |